A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
Titel:
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
Auteur:
Rosenberg, A.J. Liao, C.-Y. Karrison, T. de Souza, J.A. Worden, F.P. Libao, B. Krzyzanowska, M.K. Hayes, D.N. Winquist, E. Saloura, V. Prescott, K. Villaflor, V.M. Seiwert, T.Y. Schechter, R.B. Stadler, W.M. Cohen, E.E.W. Vokes, E.E.